)

Morphic Holding (MORF) investor relations material
Morphic Holding Jefferies 2024 Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key program updates
Morphic's ulcerative colitis Phase 2b trial is enrolling well, with strong confidence in meeting guidance for data in the first half of 2025.
Enrollment strategy balances biologic-naive and experienced patients, targeting a representative mix and at least 30% advanced therapy-experienced participants.
The oral alpha-4 beta-7 candidate is positioned as a differentiated, safe, and effective therapy, aiming for an approvable agent with a placebo-adjusted remission rate in the 10–15% range.
Phase 2a data showed strong safety, full receptor occupancy, and promising efficacy, with 25–26% remission in modified Mayo scores, though some controversy remains over endoscopic data.
A Crohn's disease study has been initiated and is in early enrollment, with updates expected as screening progresses.
Strategic and financial outlook
Morphic holds a wholly owned asset in a space with recent significant M&A activity, and is open to global partnerships if valuation is attractive.
Management is comfortable with its cash position, reporting around $700 million, and does not anticipate near-term financing needs.
Current cash runway is projected to extend well into 2027, supporting ongoing and planned clinical programs.
Guidance on trial timelines may be narrowed in the next six months, with an update on enrollment expected.
Competitive landscape and pipeline
Gilead and Takeda are pursuing similar alpha-4 beta-7 programs, with Gilead's trial design closely mirroring Morphic's; no data from Gilead's compound is available yet.
Morphic is advancing early-stage oral IL-23 and TL1A programs, with the IL-23 candidate at hit-to-lead stage and TL1A in early development.
Combination therapy strategies are being considered, with potential to follow competitors' approaches once optimal dosing is established in Phase 2b.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage